Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

Abstract
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.